Literature DB >> 6450779

Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis.

P J Heyburn, J A Child, M Peacock.   

Abstract

In order to define the relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis 22 untreated patients were studied, of whom 12 were hypercalcaemic. Most patients had malabsorption of radiocalcium from the gastrointestinal tract and evidence of increased bone resorption as assessed by fasting urinary hydroxyproline/creatinine ratio. The mean OHPr/Cr ratio, however, was similar in patients with and without hypercalcaemia. Renal failure and Bence Jones proteinuria occurred more frequently in the hypercalcaemic patients. In four patients with hypercalcaemia there was an increase in OHPr/Cr after saline infusion accompanied by an improvement in renal function and hypercalcaemia. Mithramycin given to the same patients further reduced hypercalcaemia, presumably by inhibiting bone resorption. It was concluded that the hypercalcaemia of myelomatosis is due to the combination of renal failure and increased bone resorption, but that the OHPr/Cr ratio in the untreated state is a poor indicator of the degree of bone resorption in hypercalcaemic patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6450779      PMCID: PMC1146409          DOI: 10.1136/jcp.34.1.54

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Acute renal failure associated with neoplastic disease and its treatment.

Authors:  M B Garnick; R J Mayer
Journal:  Semin Oncol       Date:  1978-06       Impact factor: 4.929

2.  Renal function in patients with multiple myeloma.

Authors:  R A DeFronzo; C R Cooke; J R Wright; R L Humphrey
Journal:  Medicine (Baltimore)       Date:  1978-03       Impact factor: 1.889

3.  Paraproteins, benign or malignant?

Authors:  J R Hobbs
Journal:  Br Med J       Date:  1967-09-16

4.  Serum calcium in a geriatric inpatient population.

Authors:  H M Hodkinson
Journal:  Age Ageing       Date:  1973-08       Impact factor: 10.668

5.  Prognostic factors in multiple myeloma.

Authors:  R Alexanian; S Balcerzak; J D Bonnet; E A Gehan; A Haut; J S Hewlett; R W Monto
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

6.  Mithramycin for hypercalcemia of malignant disease.

Authors:  T E Godfrey
Journal:  Calif Med       Date:  1971-10

7.  Treatment of osteolytic myelomatosis with mithramycin.

Authors:  T C Stamp; J A Child; P G Walker
Journal:  Lancet       Date:  1975-03-29       Impact factor: 79.321

8.  A cellulose acetate immunofixation technique.

Authors:  J Kohn; P G Riches
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

9.  Furosemide, mithramycin, and salmon calcitonin in hypercalcemia.

Authors:  J P Filastre; G Humbert; J Leroy; J Maitrot; P Deshayes; M A Canonne
Journal:  Eur J Intensive Care Med       Date:  1975-12

10.  Treatment of Paget's disease of bone with mithramycin.

Authors:  J R Condon; S B Reith; J R Nassim; F J Millard; A Hilb; E M Stainthorpe
Journal:  Br Med J       Date:  1971-02-20
View more
  1 in total

1.  Hair cortisol concentrations are associated with hippocampal subregional volumes in children.

Authors:  Attila Keresztes; Laurel Raffington; Andrew R Bender; Katharina Bögl; Christine Heim; Yee Lee Shing
Journal:  Sci Rep       Date:  2020-03-17       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.